Soﬁcopharm was created under the helm of dedicated entrepreneur and pioneer in the Egyptian medical ﬁeld Dr. Maher Scandar. He began his career in the 1950s as the acting managing director of Chemical and Industrial Pharmaceuticals, today known as CID.
The majority of the medical industry in the 1960s was public tender based and therefore for multinational companies Dr. Maher Scandar was their local representative advising them about the Middle Eastern and Egyptian market for pharmaceuticals. His clients included medical giants such as Schering, Janssen, UCB, Gruppo Lepetit and Merrell Dow Pharmaceuticals.
With the open door policy of the late 1970s Dr. Maher Scandar together with Mr. Ezzat Scandar were able to fulﬁll their ambition of creating a pharmaceutical importation and distribution company. Soﬁcopharm introduced important pharmaceutical products to the local market through the vision of its founder.
Soficopharm was built out of a need to introduce important pharmaceutical products to the local market and through the vision of its founder. As a sole distributor to the leading global companies, Soficopharm has grown its client relations and database, now providing the market with over 1000 SKUs from over 15 companies.
As an agent to the leading global companies, Soﬁcopharm has grown its client relations and database, now providing the market with over 2000+ SKUs.
Soficopharm remains a family company with second and third generation entrepreneurs leading a new era for growth. President Engineer Cherine Scandar, Vice President and Managing Director Ezzat Scandar, and COO Karim El Ashram now lead the company. With an acquired experience of over 40 years in the medical industry, the annual turnover of the company has exceeded 200+ million USD with imported pharmaceutical representation and distribution contributing to 60% of the total revenues.
We are ranked amongst the top three pharmaceutical importers and amongst the top five distributers in the country. We strive to continue our successes by investing in our teams capabilities, strengthening our existing partnerships and relationships, and increasing our distribution reach.